Related Articles
Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer
Strong impact of pathological node‑negative on long‑term overall survival of patients with triple‑negative breast cancer receiving neoadjuvant chemotherapy
PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients
Downregulation of BCSG1 may correlate with better outcome of neoadjuvant chemotherapy for triple-negative breast cancer
Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB